Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA TrialRuoxi Hong, Shusen Wang, Yue-E Teng et al.|Journal of Clinical Oncology|2025Cited by 12